NEWS
MEDIA
COVID-19 PODCAST
MEDIA
COVID-19 PODCAST

Australia's Vaccine Agreements

  • Pre
    Clinical
  • Clinical
    Phase I
  • Clinical
    Phase II
  • Clinical
    Phase III
  • Post-Licensure Surveillance
    Phase IV

In 2020, the Australian Government entered into four Advanced Purchase Agreements (APA) for the supply of COVID-19 vaccines, if they prove safe and effective. More than $3.3 billion has been invested through these agreements, putting Australia in a strong position to access safe and effective vaccines when they become available.

In 2021, three of these vaccines are still active, with the 4th (University of Queensland) withdrawn from clinical trials. Details of the three vaccines with Australian APAs are detailed below, noting that the Pfizer/BioNTech  and University of Oxford/AstraZeneca COVID-19 vaccines have been granted provisional registration from the TGA, and the Novavax COVID-19 vaccine is still in phase III clinical trials.

 

COVAX Facility

The COVAX Facility is a global initiative designed to support rapid, fair and equitable access to COVID-19 vaccines. It allows all participating countries, regardless of income levels, to have equal access to a portfolio of vaccines once they have been developed. COVAX is coordinated by Gavi with help from member countries, the Coalition for Epidemic Preparedness Innovations (CEPI), the World Health Organization, and UNICEF.

Number of vaccine candidates in portfolio
9
Number of participating countries
188

Novavax COVID-19 vaccine

Phase III
Phase 3
Platform
Protein based vaccine (nanoparticle-based vaccine)
Route
Intramuscular injection
Presentation
To be confirmed
Reconstitution required
To be confirmed
Schedule
2 doses, 21 days apart
Storage requirements
Storage, transport and handling at 2-8°C
Common side effects
Headache, fatigue and myalgia

Pfizer | BioNTech COVID-19 vaccine

Phase IV
Post-Licensure Surveillance
Platform
Genetic vaccine (mRNA)
Route
Intramuscular injection
Presentation
Multi dose vial (once reconstituted contains 5 doses of 0.3ml per dose)
Reconstitution required
Yes. Once thawed, dilute with 1.8 mL of sterile 0.9% sodium chloride to give 5 doses of 0.3 ml per dose
Schedule
2 doses, 21 days apart
Storage requirements
Storage at -70°C, transport on dry ice, once thawed will remain stable for 5 days at 2-8°C
Common side effects
Mild to moderate pain at the injection site, fatigue, headache and muscle aches

University of Oxford | AstraZeneca COVID-19 vaccine

Phase IV
Post-Licensure Surveillance
Platform
Viral vector vaccine
Route
Intramuscular injection
Presentation
Multi dose vial (contains 10 doses of 0.5ml per dose)
Reconstitution required
No
Schedule
2 doses, 4-12 weeks apart
Storage requirements
Storage, transport and handling at 2-8°C
Common side effects
Pain and tenderness at the injection site, fatigue, headache, and flu-like symptoms